Prestige Consumer Healthcare (NYSE:PBH) Upgraded by StockNews.com to “Buy” Rating

StockNews.com upgraded shares of Prestige Consumer Healthcare (NYSE:PBH) from a hold rating to a buy rating in a report released on Wednesday morning.

PBH has been the topic of several other reports. DA Davidson reiterated a “buy” rating and issued a $95.00 target price on shares of Prestige Consumer Healthcare in a report on Monday, November 11th. Sidoti cut shares of Prestige Consumer Healthcare from a “buy” rating to a “neutral” rating and set a $90.00 price target for the company. in a research note on Monday, December 9th. Finally, Jefferies Financial Group reaffirmed a “hold” rating and issued a $76.00 target price (up previously from $70.00) on shares of Prestige Consumer Healthcare in a research report on Tuesday, September 24th. Two research analysts have rated the stock with a hold rating and three have given a buy rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $85.25.

Prestige Consumer Healthcare Stock Performance

PBH stock opened at $78.79 on Wednesday. The company has a 50 day moving average price of $78.86 and a 200 day moving average price of $72.90. The stock has a market capitalization of $3.89 billion, a PE ratio of 19.17, a price-to-earnings-growth ratio of 2.32 and a beta of 0.49. Prestige Consumer Healthcare has a fifty-two week low of $57.95 and a fifty-two week high of $86.36. The company has a debt-to-equity ratio of 0.61, a current ratio of 3.56 and a quick ratio of 2.10.

Prestige Consumer Healthcare (NYSE:PBH) last issued its quarterly earnings results on Thursday, November 7th. The company reported $1.09 EPS for the quarter, hitting the consensus estimate of $1.09. The company had revenue of $283.79 million during the quarter, compared to analysts’ expectations of $282.09 million. Prestige Consumer Healthcare had a net margin of 18.54% and a return on equity of 12.23%. Prestige Consumer Healthcare’s revenue was down .9% on a year-over-year basis. During the same quarter in the previous year, the company earned $1.07 EPS. Analysts forecast that Prestige Consumer Healthcare will post 4.44 EPS for the current year.

Insider Activity at Prestige Consumer Healthcare

In other Prestige Consumer Healthcare news, CEO Ronald M. Lombardi sold 10,875 shares of the business’s stock in a transaction that occurred on Tuesday, November 19th. The shares were sold at an average price of $82.60, for a total transaction of $898,275.00. Following the completion of the transaction, the chief executive officer now directly owns 320,952 shares in the company, valued at $26,510,635.20. The trade was a 3.28 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, insider William P’pool sold 8,987 shares of the company’s stock in a transaction on Tuesday, November 12th. The stock was sold at an average price of $81.85, for a total value of $735,585.95. Following the sale, the insider now owns 20,058 shares of the company’s stock, valued at approximately $1,641,747.30. This represents a 30.94 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 38,810 shares of company stock worth $3,187,300. Corporate insiders own 1.60% of the company’s stock.

Institutional Investors Weigh In On Prestige Consumer Healthcare

Hedge funds and other institutional investors have recently bought and sold shares of the company. Lombard Odier Asset Management USA Corp acquired a new position in shares of Prestige Consumer Healthcare during the second quarter worth $550,000. Sequoia Financial Advisors LLC grew its holdings in Prestige Consumer Healthcare by 12.9% in the third quarter. Sequoia Financial Advisors LLC now owns 9,824 shares of the company’s stock worth $708,000 after purchasing an additional 1,120 shares during the period. Pinnacle Associates Ltd. increased its position in Prestige Consumer Healthcare by 60.3% in the 3rd quarter. Pinnacle Associates Ltd. now owns 24,630 shares of the company’s stock valued at $1,776,000 after buying an additional 9,269 shares in the last quarter. Ariel Investments LLC increased its holdings in shares of Prestige Consumer Healthcare by 10.7% during the second quarter. Ariel Investments LLC now owns 2,835,203 shares of the company’s stock valued at $195,204,000 after acquiring an additional 274,212 shares in the last quarter. Finally, Citigroup Inc. increased its stake in Prestige Consumer Healthcare by 66.6% during the 3rd quarter. Citigroup Inc. now owns 76,772 shares of the company’s stock valued at $5,535,000 after purchasing an additional 30,677 shares in the last quarter. Institutional investors own 99.95% of the company’s stock.

About Prestige Consumer Healthcare

Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare.